SCHEMBL19684692

SCHEMBL19684692

CC(C)(C)OC(=O)N1CCc2cc(Cl)ccc2C1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 5/20 0.78
NR1H2 P55055 1/20 0.64
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
ESR1 P03372 4/20 0.49
MAPK1 P28482 1/20 0.48
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
ABHD6 Q9BV23 2/20 0.46
HDAC1 Q13547 1/20 0.46
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
STS P08842 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
NAMPT P43490 1/20 0.44
OXTR P30559 1/20 0.44
AVPR1A P37288 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31621670 1.00 ESR2 (0.78) ESR2NR1H2MEN1KMT2AESR1
SCHEMBL29388008 0.95 NR1H2 (0.72) ESR2NR1H2MEN1KMT2AESR1
SCHEMBL506273 0.92 ESR2 (0.65) ESR2NR1H2MEN1KMT2ALMNA
SCHEMBL7804799 0.90 ESR2 (0.71) ESR2NR1H2MEN1KMT2AESR1
SCHEMBL8223384 0.89 ESR2 (0.60) ESR2NR1H2MEN1KMT2AMAPK1
SCHEMBL450677 0.88 ESR2 (1.00) ESR2NR1H2ESR1MAPK1ABHD6
SCHEMBL29590844 0.88 ESR2 (1.00) ESR2NR1H2ESR1MAPK1ABHD6
SCHEMBL7811245 0.86 ESR2 (0.70) ESR2NR1H2MEN1KMT2AESR1
SCHEMBL2095898 0.85 ESR2 (0.76) ESR2NR1H2ESR1MAPK1ABHD6
SCHEMBL2056208 0.85 ESR2 (0.76) ESR2NR1H2MEN1KMT2AESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP ESR2 2951/4885NR1H2 3021/4885MEN1 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.